Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 5:59 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 865–888 of 7,443 matching trials from the live ClinicalTrials.gov search.
Filters: Aurora, Colorado Clear all
Completed Not applicable Interventional Accepts healthy volunteers

Environmental Influences on Early Childhood Obesity

NCT02703688
View directory record Official record
Conditions
Childhood Obesity
Interventions
Healthy Homes, Usual Care
Behavioral · Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
3 Years to 5 Years
Enrollment
129 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jul 15, 2022 · Synced Nov 9, 2026, 5:59 PM EST
Active, not recruiting No phase listed Observational

A Multicenter, Prospective, Long-term, Observational Registry of Pediatric Patients With Inflammatory Bowel Disease

NCT00606346
View directory record Official record
Conditions
Crohn's Disease, Ulcerative Colitis, Indeterminate Colitis, Inflammatory Bowel Diseases
Interventions
Anti TNF therapy including infliximab, No Biologics
Biological · Drug
Lead sponsor
Janssen Biotech, Inc.
Industry
Eligibility
1 Month to 17 Years
Enrollment
4,970 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2038
U.S. locations
58
States / cities
Mobile, Alabama • Phoenix, Arizona • Los Angeles, California + 55 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2026 · Synced Nov 9, 2026, 5:59 PM EST
Completed Phase 3 Interventional Results available

The COREG And Lisinopril Combination Therapy In Hypertensive Subjects (COSMOS) Trial

NCT00347360
View directory record Official record
Conditions
Hypertension
Interventions
lisinopril, carvedilol controlled release formulation
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
654 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
151
States / cities
Anniston, Alabama • Birmingham, Alabama • Haleyville, Alabama + 131 more
Source: ClinicalTrials.gov public record
Updated Dec 26, 2016 · Synced Nov 9, 2026, 5:59 PM EST
Completed Phase 1 Interventional

Study of Cobimetinib in Combination With Atezolizumab and Bevacizumab in Participants With Gastrointestinal and Other Tumors

NCT02876224
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Atezolizumab, Bevacizumab, Cobimetinib
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
4
States / cities
Aurora, Colorado • New York, New York • Nashville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2019 · Synced Nov 9, 2026, 5:59 PM EST
Completed Phase 1 Interventional Results available

Pharmacokinetics and Safety of Regorafenib (BAY73-4506) in Cancer Subjects With Severe Renal Impairment

NCT01853046
View directory record Official record
Conditions
Neoplasms
Interventions
Regorafenib (Stivarga, BAY73-4506)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
5
States / cities
Los Angeles, California • Aurora, Colorado • St Louis, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2017 · Synced Nov 9, 2026, 5:59 PM EST
Completed Phase 2 Interventional

Safety & Efficacy Study of AT-101 in Combination w/ Rituximab in Previously Untreated Grade I-II Follicular Non-Hodgkin's Lymphoma

NCT00440388
View directory record Official record
Conditions
Follicular Lymphoma
Interventions
AT-101, Rituximab
Drug
Lead sponsor
Ascenta Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
28
States / cities
Birmingham, Alabama • Phoenix, Arizona • Aurora, Colorado + 25 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2010 · Synced Nov 9, 2026, 5:59 PM EST
Terminated Phase 4 Interventional Results available

Combined Use of BIOTRONIK Home Monitoring and Predefined Anticoagulation to Reduce Stroke Risk

NCT00559988
View directory record Official record
Conditions
Atrial Fibrillation, Atrial Flutter, Stroke, Embolism, Systemic Arterial, Major Bleeding
Interventions
Home Monitoring Guided OAC, Physician-Directed OAC
Drug
Lead sponsor
Biotronik, Inc.
Industry
Eligibility
18 Years and older
Enrollment
2,718 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
73
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Anaheim, California + 70 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2017 · Synced Nov 9, 2026, 5:59 PM EST
Completed Phase 3 Interventional

Enzastaurin Versus Lomustine in Glioblastoma

NCT00295815
View directory record Official record
Conditions
Glioblastoma
Interventions
enzastaurin, lomustine
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
397 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
42
States / cities
Phoenix, Arizona • Tucson, Arizona • Berkeley, California + 39 more
Source: ClinicalTrials.gov public record
Updated Sep 12, 2019 · Synced Nov 9, 2026, 5:59 PM EST
Completed Not applicable Interventional Results available

Reducing Clinical Inertia in Hypertension Treatment: A Pragmatic Trial

NCT01145391
View directory record Official record
Conditions
Hypertension
Interventions
Active Outreach to Patients and Providers
Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 79 Years
Enrollment
591 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Aug 15, 2018 · Synced Nov 9, 2026, 5:59 PM EST
Completed No phase listed Observational Accepts healthy volunteers Results available

COVID-19 Antibody and Reinfection Study

NCT05365750
View directory record Official record
Conditions
COVID-19 Testing
Interventions
Not listed
Lead sponsor
Kaiser Permanente
Other
Eligibility
18 Years and older
Enrollment
4,235 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 18, 2025 · Synced Nov 9, 2026, 5:59 PM EST
Completed Not applicable Interventional Accepts healthy volunteers

Computerized Cognitive Behavioral Treatment for Insomnia: Improving Rural Veteran Access to Evidence-Based Treatment to Reduce Suicide Risk (R-Vets Sleep)

NCT03365024
View directory record Official record
Conditions
Insomnia, Mental Health Functioning, Physical Health Functioning
Interventions
Computerized Cognitive Behavioral Therapy for Insomnia, Sleep Education
Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 89 Years
Enrollment
93 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jul 28, 2021 · Synced Nov 9, 2026, 5:59 PM EST
Active, not recruiting Phase 2 Interventional Results available

Enzalutamide for Patients With Androgen Receptor Positive Salivary Cancers

NCT02749903
View directory record Official record
Conditions
Androgen Receptor Positive, Locally Advanced Salivary Gland Carcinoma, Metastatic Salivary Gland Carcinoma, Salivary Duct Carcinoma, Salivary Gland Adenocarcinoma, NOS, Salivary Gland Basal Cell Adenocarcinoma, Stage III Major Salivary Gland Cancer AJCC v7
Interventions
enzalutamide
Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2028
U.S. locations
287
States / cities
Anchorage, Alaska • Anaheim, California • Baldwin Park, California + 201 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Nov 9, 2026, 5:59 PM EST
Completed Phase 3 Interventional

Effect of Tumor Treating Fields (TTFields, 200 kHz) Concomitant With Weekly Paclitaxel for the Treatment of Recurrent Ovarian Cancer (ENGOT-ov50 / GOG-3029 / INNOVATE-3)

NCT03940196
View directory record Official record
Conditions
Ovarian Cancer
Interventions
NovoTTF-100L(O), Paclitaxel
Device · Drug
Lead sponsor
NovoCure Ltd.
Industry
Eligibility
18 Years and older · Female only
Enrollment
540 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
59
States / cities
Phoenix, Arizona • Tucson, Arizona • La Jolla, California + 50 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2024 · Synced Nov 9, 2026, 5:59 PM EST
Completed Phase 3 Interventional Results available

Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer

NCT00265850
View directory record Official record
Conditions
Colorectal Cancer
Interventions
bevacizumab, cetuximab, FOLFOX or, FOLFIRI
Biological · Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
2,334 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2018
U.S. locations
662
States / cities
Mobile, Alabama • Anchorage, Alaska • Fort Smith, Arkansas + 468 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2026 · Synced Nov 9, 2026, 5:59 PM EST
Completed Phase 1Phase 2 Interventional

CAB-AXL-ADC Safety and Efficacy Study in Adult and Adolescent Patients With Sarcoma

NCT03425279
View directory record Official record
Conditions
Undifferentiated Pleomorphic Sarcoma, Myxofibrosarcoma
Interventions
CAB-AXL-ADC, PD-1 inhibitor
Biological
Lead sponsor
BioAtla, Inc.
Industry
Eligibility
12 Years and older
Enrollment
245 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
35
States / cities
Tucson, Arizona • Los Angeles, California • San Francisco, California + 24 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2025 · Synced Nov 9, 2026, 5:59 PM EST
Completed Phase 3 Interventional

Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Previously Untreated Advanced or Metastatic Squamous Non-Small Cell Lung Cancer

NCT02106546
View directory record Official record
Conditions
Squamous Non-Small Cell Lung Cancer
Interventions
Carboplatin, Veliparib, Paclitaxel, Placebo to veliparib
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 99 Years
Enrollment
970 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
38
States / cities
Jonesboro, Arkansas • Los Angeles, California • Aurora, Colorado + 30 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2020 · Synced Nov 9, 2026, 5:59 PM EST
Completed Phase 1 Interventional

Safety, Pharmacokinetics (PK) of AKT and MEK Combination

NCT01138085
View directory record Official record
Conditions
Cancer
Interventions
GSK1120212, GSK2141795
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
10
States / cities
Aurora, Colorado • New Haven, Connecticut • Boston, Massachusetts + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2017 · Synced Nov 9, 2026, 5:59 PM EST
Not yet recruiting Phase 3 Interventional

PRISE (Personalized Response and Immunologic Surveillance of Endogenous C-Peptide Preservation in New, Recent, and Established Onset Type 1 Diabetes Treated With Human Anti-Thymocyte Globulin [h-ATG]) Study

NCT07670650
View directory record Official record
Conditions
Type 1 Diabetes (T1D)
Interventions
SAB-142, Placebo
Drug
Lead sponsor
University of Florida
Other
Eligibility
5 Years to 40 Years
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
4
States / cities
San Francisco, California • Aurora, Colorado • Gainesville, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2026 · Synced Nov 9, 2026, 5:59 PM EST
Terminated Phase 4 Interventional Results available

Optimal Treatment for Recurrent Clostridium Difficile

NCT02667418
View directory record Official record
Conditions
Clostridium, Difficile, Fidaxomicin, Vancomycin
Interventions
Fidaxomicin, Vancomycin with Taper/Pulse, Vancomycin
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
308 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
32
States / cities
Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 28 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Nov 9, 2026, 5:59 PM EST
Terminated Phase 3 Interventional Results available

This Was an Open-label, Single-arm Extension Study (CFTY720D2306E1) to a Double-blind, Randomized Multicenter, Placebo-controlled, Parallel-group Core Study (CFTY720D2306) in PPMS.

NCT00731692
View directory record Official record
Conditions
Primary Progressive Multiple Sclerosis
Interventions
FTY720, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
25 Years to 65 Years
Enrollment
970 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
33
States / cities
Newport Beach, California • Sacramento, California • Aurora, Colorado + 29 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2017 · Synced Nov 9, 2026, 5:59 PM EST
Completed Phase 3 Interventional Results available

A Study in the Treatment of Children and Adolescents With Major Depressive Disorder

NCT00849693
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Placebo, fluoxetine, duloxetine
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
7 Years to 17 Years
Enrollment
463 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
44
States / cities
Birmingham, Alabama • Dothan, Alabama • Little Rock, Arkansas + 41 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2012 · Synced Nov 9, 2026, 5:59 PM EST
Terminated Phase 1 Interventional

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7759065 as a Single Agent and in Combination With Atezolizumab in Patients With Locally Advanced or Metastatic Solid Tumors

NCT06488716
View directory record Official record
Conditions
Solid Tumour
Interventions
RO7759065, Atezolizumab
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
4
States / cities
Duarte, California • Aurora, Colorado • New Brunswick, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 24, 2025 · Synced Nov 9, 2026, 5:59 PM EST
Active, not recruiting No phase listed Observational

Prospective Evaluation of De-Escalation From antiCD-20 Therapies to Dimethyl Fumarate (Tecfidera) or Diroximel Fumarate (Vumerity)

NCT07757568
View directory record Official record
Conditions
Multiple Sclerosis (MS) Relapsing Remitting
Interventions
Vumerity, Tecfidera
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Nov 9, 2026, 5:59 PM EST
Recruiting No phase listed Observational

Study to Evaluate Biological & Clinical Effects of Significantly Corrected CFTR Function in Infants & Young Children

NCT04509050
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Ivacaftor or elexacaftor/tezacaftor/ivacaftor
Drug
Lead sponsor
Sonya Heltshe
Other
Eligibility
Up to 10 Years
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
35
States / cities
Birmingham, Alabama • Palo Alto, California • Aurora, Colorado + 31 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Nov 9, 2026, 5:59 PM EST